Acute Mesenteric IschemiaBIPAMINCT06212921
Biomarkers in Prediction of AMI
A study testing Sequential blood samples in people with Acute Mesenteric Ischemia, run by University of Tartu at 2 sites in 2 countries.
Trial summary
Current study will be undertaken to identify combinations of biomarkers that can reliably identify acute mesenteric ischaemia (AMI) and distinguish between non-transmural and transmural ischaemia. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Mesenteric Ischemia
- What is being tested?
- Sequential blood samples
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 256 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 14 Oct 2024to 31 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older
- Initial decision in favour of further diagnostics of mesenteric ischaemia
Who cannot join
- Age <18 years
- Consent declined by patient or next of kin (delayed consent)
- Chronic mesenteric ischaemia without an acute event
- Immediate decision for withdrawal of further diagnostics and active treatment
- Referral from another hospital with already established diagnosis of AMI
- AMI diagnosed at surgery without previously having been considered
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
About this study
Official title: Biomarkers In Prediction of Acute Mesenteric Ischaemia: a Prospective Multicentre Study (BIPAMI Study)
Current study will be undertaken to identify combinations of biomarkers that can reliably identify acute mesenteric ischaemia (AMI) and distinguish between non-transmural and transmural ischaemia. Different combinations of biomarkers for different sub-types and severity of AMI, and different time points of measurement after onset of symptoms.
- Conditions
- Acute Mesenteric Ischemia
- Being tested
- Sequential blood samples
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sequential blood samplesDiagnostic test
Sequential blood samples for diagnostic tests is the only intervention in thei study
| Study group | Role | What they receive |
|---|---|---|
| Patient with suspicion of acute mesenteric ischaemia | Other | Bolld samples is the only intervention. All patients with suspicion of AMI will be included and blood samples collected Receives: Diagnostic Test: Sequential blood samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of correctly predicted cases of acute mesenteric ischaemia
Rate of correctly predicted cases of Acute mesenteric ischaemia using different biomarkers
Measured: 10 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jan 2024
- Study start14 Oct 2024
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Mesenteric IschemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Sequential blood samples will be collected from study subjects
- Masking
- None (open label)
- Enrolment
- 256 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Tartu
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Annika Reintam Blaser, University of Tartu
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06212921
- Sponsor's protocol ID
- BIPAMI study
- Acronym
- BIPAMI
- Status last verified
- Nov 2026
- First submitted
- 4 Jan 2024
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Tamme K, Acosta S, Biloslavo A, Bjorck M, Casian D, Damaskos D, Forbes A, Kase K, Kisand K, Lakbar I, Mihnovits V, Murruste M, Mandul M, Nuzzo A, Padar M, Starkopf J, Visconti D, Reintam Blaser A. Biomarkers In Prediction of Acute Mesenteric Ischaemia: a prospective multicentre study (BIPAMI study): a study protocol. BMC Surg. 2024 Jul 3;24(1):201. doi: 10.1186/s12893-024-02491-3.
PubMed 38961419
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biomarkers In Prediction of Acute Mesenteric Ischaemia: a Prospective Multicentre Study (BIPAMI Study)
- ClinicalTrials.gov ID
- NCT06212921
- Acronym / sponsor ID
- BIPAMI / BIPAMI study
- Conditions
- Acute Mesenteric Ischemia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 256 participants (actual)
- Lead sponsor
- University of TartuUniversity, hospital or other
- Study start
- 14 Oct 2024 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 19 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Current study will be undertaken to identify combinations of biomarkers that can reliably identify acute mesenteric ischaemia (AMI) and distinguish between non-transmural and transmural ischaemia. Different combinations of biomarkers for different sub-types and severity of AMI, and different time points of measurement after onset of symptoms.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Sequential blood samples will be collected from study subjects
| Arm | Type | Receives |
|---|---|---|
| Patient with suspicion of acute mesenteric ischaemia | Other | Diagnostic Test: Sequential blood samplesBolld samples is the only intervention. All patients with suspicion of AMI will be included and blood samples collected |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Age 18 years or older
- Initial decision in favour of further diagnostics of mesenteric ischaemia
Key exclusion criteria (6 listed)
- Age <18 years
- Consent declined by patient or next of kin (delayed consent)
- Chronic mesenteric ischaemia without an acute event
- Immediate decision for withdrawal of further diagnostics and active treatment
- Referral from another hospital with already established diagnosis of AMI
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sequential blood samplesSequential blood samples for diagnostic tests is the only intervention in thei study | Diagnostic test | Patient with suspicion of acute mesenteric ischaemia |
Primary outcome
Rate of correctly predicted cases of acute mesenteric ischaemia
Time frame: 10 months
Rate of correctly predicted cases of Acute mesenteric ischaemia using different biomarkers
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Derived from this study: PubMed 38961419Tamme K, Acosta S, Biloslavo A, Bjorck M, Casian D, Damaskos D, Forbes A, Kase K, Kisand K, Lakbar I, Mihnovits V, Murruste M, Mandul M, Nuzzo A, Padar M, Starkopf J, Visconti D, Reintam Blaser A. Biomarkers In Prediction of Acute Mesenteric Ischaemia: a prospective multicentre study (BIPAMI study): a study protocol. BMC Surg. 2024 Jul 3;24(1):201. doi: 10.1186/s12893-024-02491-3.
- Individual participant dataSharing planned: No
Related trials for Acute Mesenteric Ischemia
Recruiting
Evaluation of the Discriminative Abilities of Biomarkers for the Diagnosis of Acute Mesenteric Ischemia Compared With Another Similar Clinical Presentation: a Pilot Study
Acute Mesenteric Ischemia
Active, not recruiting
ThromBus Aspiration for Acute Mesenteric Artery Occlusion With Emergent Laparoscopic Surgery
Acute Mesenteric Ischemia
RecruitingObservational study
Predictors of Transmural Non-Occlusive Mesenteric Ischemia in ICU Patients With Suspected Acute Mesenteric Ischemia
Non-Occlusive Mesenteric Ischaemia (NOMI), Acute Mesenteric Ischemia
RecruitingObservational study
Assessment of Quality of Life After Acute Mesenteric Ischemia
Acute Mesenteric Ischemia
Recruiting
Searching Biomarkers of Acute Intestinal Ischemic Injuries
Acute Mesenteric Ischemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sequential blood samples in people with Acute Mesenteric Ischemia, run by University of Tartu at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Estonia, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of correctly predicted cases of acute mesenteric ischaemia (time frame: 10 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06212921, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.